← Back to Treatments
🏅 FDA Orphan Designation

Rethymic

allogeneic processed thymus tissue-agdc

Manufacturer: Enzyvant Therapeutics GmbH

Indicated for:
T-cell immunodeficiency with thymic aplasiaOrphan

FDA-Approved Indications (1)

immune reconstitution in pediatric patients with congenital athymia

Indications & Usage

1 INDICATIONS AND USAGE RETHYMIC ® is indicated for immune reconstitution in pediatric patients with congenital athymia. RETHYMIC is indicated for immune reconstitution in pediatric patients with congenital athymia. ( 1 ) Limitations of Use : RETHYMIC is not indicated for the treatment of patients with severe combined immunodeficiency (SCID). Limitations of Use RETHYMIC is not indicated for the treatment of patients with severe combined immunodeficiency (SCID).

💙 Support Programs

View all →
Rethymic
Enzyvant Therapeutics GmbH

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.